Compare NX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | IVA |
|---|---|---|
| Founded | 1927 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.1M | 883.8M |
| IPO Year | 2008 | N/A |
| Metric | NX | IVA |
|---|---|---|
| Price | $15.42 | $4.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $28.00 | $16.20 |
| AVG Volume (30 Days) | 312.5K | ★ 466.4K |
| Earning Date | 06-04-2026 | 03-30-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,837,641,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.77 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $2.94 |
| 52 Week High | $22.90 | $7.98 |
| Indicator | NX | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 31.35 | 32.13 |
| Support Level | $15.57 | $3.77 |
| Resistance Level | $20.81 | $4.67 |
| Average True Range (ATR) | 0.82 | 0.32 |
| MACD | -0.12 | -0.12 |
| Stochastic Oscillator | 3.21 | 12.35 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.